Ursodeoxycholic acid- an intervention worth pursuing



PSC Partners 2011



Gideon Hirschfield




Conflict of interest statement

Company Name	Relationship
Intercept Pharma	Consultant, Investigator
Axcan Pharma	Speaker, Consultant
Centocor	Advisory board, Consultant
BMS	Investigator
Boehringer Ingelheim	Investigator
Tibotec	Investigator
Sanofi-Aventis	Advisory board
Merck	Speaker, Research support
Roche	Speaker






Over past 24 months



A slow disease that we are determined to change





Journal of Hepatology (2009) 158-164

PSC in 1980- LATE PRESENTATION

Table 2 Laboratory investigations

	No.			Primary sclerosing cholangitis				
		range	Mean	Range	% Abnormal			
Bilirubin								
(µmol/l)	29	0-17	84	9-459	83			
Alkaline phosphatase								
(KAU/I)	29	3-13	69	6–172	97			
Amino transferase								
(IU/I)	29	4-15	62	19-226	97			
Albumin (g/l)	28	35-50	39	25-47	29			
IgM (g/l)	20	0.7-2.8	3.28	0.8-11.7	45			





Chapman et al. Gut 1980

2011 – EARLY PRESENTATION: TIME TO INTERVENE

Factor	Category	Sub Category	All (N = 199)	Men (n = 142)	Women (n = 57)
Age in years, median (range)			38.5 (18.0-76.8)	38.7 (18.2-73.9)	37.6 (18.0-76.8)
Inflammatory bowel disease (IBD)	Yes	Any IBD	152 (76.4%)	117 (82.4%)	35 (61.4%)
-		Ulcerative colitis	129 (64.8%)	104 (73.2%)	25 (43.9%)
		Crohn disease	17 (8.5%)	9 (6.3%)	8 (14.0%)
l de la constante de la consta		Indeterminate colitis	5 (2.5%)	3 (2.1%)	2 (3.5 %)
l de la constante de la consta		Microscopic colitis	1 (0.5%)	1 (0.7%)	0 (0%)
l de la constante de la consta	No		47 (23.6%)	25 (17.6%)	22 (38.6%)
Extension of biliary involvement	Only intrahepatic		61 (30.7%)	47 (33.1%)	14 (24.6%)
	Extrahepatic and/or intrahepatic		115 (57.8%)	81 (57.0%)	34 (59.6%)
l de la constante de la consta	Small duct disease		20 (10.1%)	12 (8.5%)	8 (14.0%)
l de la constante de la consta	Unknown		3 (1.5%)	2 (1.4%)	1 (1.8%)
Symptoms at diagnosis	Yes	Any symptom	93 (46.7%)	62 (43.7%)	31 (54.4%)
		Jaundice	48 (24.1%)	32 (22.5%)	16 (28.1%)
l de la constante de la consta	(Cholangitis	19 (9.5%)	13 (9.2%)	6 (10.5%)
l de la constante de la consta		Itching	20 (10.1%)	14 (9.9%)	6 (10.5%)
l de la constante de la consta		Abdominal pain	50 (25.1%)	34 (23.9%)	16 (28.1%)
l de la constante de la consta		Other	66 (33.2%)	48 (33.8%)	18 (31.6%)
	No		106 (53.3%)	80 (56.3%)	26 (45.6%)





Secondary sclerosing cholangitis




The variety of secondary causes mimicking histologic and radiological features of PSC (including autoimmunity, **TRE** ischemia, infection and toxins) suggests commonality in final pathways associated with biliary injury

TORON



Mdr2 deficient mice develop cholangiopathy






IS FROM BILE ACID TOXICITY Gastroenterology 2002;123:1238–1251



UDCA – an ancient bear treatment


UDCA had been isolated in Japan in 1927 from dried bile of the black bear ("Yutan") which was used in traditional Chinese and Japanese medicine as a remedy for liver and gastrointestinal disorders for centuries.







Bile constituents






Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 9th ed.




Major primary and secondary bile acids and their sites of synthesis and metabolism





Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 9th ed.

Major targets of ursodeoxycholic acid therapy in cholestatic liver diseases- a good liver tonic






HEPATOLOGY, Vol. 51, No. 4, 2010



Beuers U et al.


Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.







RCT: UDCA (23mg/kg/d) vs Placebo



TORONTO WESTERN HOSPITAL

Symptoms and biochemistry

Table 3 Effect on symptoms and biochemical values of ursodeoxycholic acid treatment in the trials included in meta-analysis

Fatigue	Denveltere							
Bac	Pruritus	AST	ALT	γ-GT	ALP	Bilirubin	Albumin	Mayo score
_	_	++	++	++	++	++	NR	+
-	_	+	NR	+	+	+	NR	NR
-	_	NR	++	++	++	+	_	_
NR	NR	NR	NR	NR	NR	NR	NR	NR
-	_	+	NR	++	++	+	_	NR
NR	NR	++	NR	NR	++	++	_	NR
_	_	+	NR	++	++	+	_	NR
NR	-	NR	+	NR	+	+	-	NR
	- - NR - NR - NR	- – – – NR NR – – NR NR – – NR NR	++ + NR NR NR + NR NR ++ NR NR ++ +	++ ++ + NR NR ++ NR NR NR NR + NR NR NR ++ NR + NR + NR	- - ++ ++ ++ - - + NR + - - + NR ++ NR NR NR NR NR - - + NR ++ NR NR NR NR ++ NR NR ++ NR ++ NR NR ++ NR NR - - + NR NR - - + NR ++	- - +++ ++ ++ - - + NR + + - - + NR ++ ++ NR NR NR NR NR NR - - + NR NR NR - - + NR ++ ++ NR NR ++ NR ++ ++ NR NR ++ NR NR ++ - - + NR NR ++ - - + NR ++ ++	- - ++ ++ ++ ++ ++ - - + NR + + + - - + NR ++ ++ + NR NR NR NR NR NR - - + NR NR NR - - + NR ++ ++ NR NR NR + ++ ++ NR NR ++ NR ++ ++ - - + NR NR ++ ++ - - + NR NR ++ ++	- - ++ ++ ++ ++ NR - - + NR + + + NR - - + NR ++ ++ + + NR - - NR NR NR NR NR NR - - + NR NR NR NR NR - - + NR NR NR NR NR - - + NR ++ ++ + - NR NR NR NR NR ++ ++ - NR NR ++ NR NR ++ ++ - - - + NR NR ++ ++ ++ - - - + NR ++ ++ ++ - - - - - + NR ++ ++ ++ ++ -

–, No significant change; +, improvement trend comparing UDCA with placebo or no treatment; ++, significant improvement. γ -GT, gamma glutamyl transpeptidase; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; NR, not reported.





Hepatology Research 2009; **39**: 865–873



High dose UDCA vs Placebo

Model of All Primary Endpoints







HEPATOLOGY, Vol. 50, No. 3, 2009



Still relatively few patients studied

Table 1. Selected Trials of Ursodeoxycholic Acid for Treatment of Primary Sclerosing Cholangitis

First Author	Year Published	No. of Patients	Dose of UDCA/Day	Type of Trial	Trial Period (Months)	LFTS Improved?	Symptoms Improved?	Liver Histology Improved?
Beuers ⁶	1992	6	13-15 mg/kg	Double-blind, placebo-controlled	12	Y	N	Y
Stiehl7	1994	20	750 mg	Double-blind, placebo-controlled	12-48	Y	Ν	Y
Lindor ⁸	1997	105	13-15 mg/kg	Double-blind, placebo-controlled	34	Y	Ν	Ν
Mitchell ¹⁰	2001	26	20-25 mg/kg	Double-blind, placebo-controlled	24	Y	Ν	Y
Harnois ¹³	2001	30	25-30 mg/kg	Open label	12	Y	Not done	Not done
Okolicsanyi ²³	2002	86	8-13 mg/kg	Open-label, placebo-controlled	120	Y	Y	Ν
Olsson ¹¹	2004	110	17-23 mg/kg	Double-blind, placebo-controlled	60	Y	Ν	Not done
Lindor ⁹	2009	150	25-30 mg/kg	Double-blind, placebo-controlled	60	Y	Ν	Ν



HEPATOLOGY, Vol. 50, No. 3, 2009




We're all different: one size for all might not fit







Kaplan–Meier estimates of proportion of patients without dysplasia and carcinoma after taking ursodeoxycholic acid (Urso) or placebo.





Pardi DS, Loftus EV, Jr, Kremers WK, et al . Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889–93



UDCA- Pro-Establishment...

- Safe (normal dose)
- Reduces liver biochemical inflammation
- Studies looking at survival are frought with challenges
- Can't expect it cures but may slow down disease in a subgroup
- Continue to offer patients the choice of therapy at normal dose





Cochrane review

- Eight trials evaluated UDCA versus placebo or no intervention (592 patients). The eight randomised clinical trials have a high risk of bias.
- Patients were treated for three months to six years (median three years). The dosage of UDCA used in the trials ranged from low (10 mg/kg body weight/day) to high (28 to 30 mg/kg body weight/day).
- Ursodeoxycholic acid did not significantly reduce the risk of death (RR 1.00; 95% CI 0.46 to 2.20); treatment failure including liver transplantation, varices, ascites, and encephalopathy (RR 1.22; 95% CI 0.91 to 1.64); liver histological deterioration (RR 0.89; 95% CI 0.45 to 1.74); or liver cholangiographic deterioration (RR 0.60; 95% CI 0.23 to 1.57).
- Ursodeoxycholic acid significantly improved serum bilirubin (MD -14.6 µmol/litre; 95% CI -18.7 to -10.6), alkaline phosphatases (MD -506 IU/litre; 95% CI -583 to -430), aspartate aminotransferase (MD -46 IU/litre; 95% CI 77 to -16), and gamma-glutamyltranspeptidase (MD -260 IU/litre; 95% CI 315 to -205), but not albumin (MD -0.20 g/litre; 95% CI -1.91 to 1.50).
- Ursodeoxycholic acid was safe and well tolerated by patients with primary sclerosing cholangitis.





Study	n	RCT	Duration (y)	Dose (mg/day)	Laboratory tests	Histology	Symptoms	ERC	Survival
Hayashi ¹⁰	1	_	2	600	+	0	NE	_	NE
Chazouillers ¹¹	15	_	0.5	750-1250	+	NE	0	NE	NE
O'Brien ¹²	12	_	1.5	10/kg	+	NE	+	NE	NE
Beuers ¹³	14	+	1	13–15/kg	+	+	0	NE	_
Stiehl ¹⁴	27	_	1	750	+	NE	+	NE	NE
	20	+	0.25	750	+	NE	0	NE	_
	12	_	1	750	+	+	+	а	NE
De Maria ¹⁵	40	+	2	600	0	NE	0	0	0
Lindor ⁶	102	+	2.2	13–15/kg	+	0	0	NE	0
Van Hoogstraten ¹⁶	48	_	2	10/kg	+	0	0	0	0
Mitchell ¹⁷	26	+	2	20/kg	+	+	0	NE	NE
Harnois ¹⁸	30	_	1	25-30/kg	+	NE	NE	NE	+ b
Okolicsanyi ¹⁹	86	_	≈4	8-13/kg	+	+	NE	NE	NE
Schramm ^{20c}	15	_	4.5	500-750	_	+	NE	d	b
Färkkilä ^{22e}	80	+	3	15/kg	+	+	NE	0	0
Stiehl ^{23f}	65	_	≈4	750	+	NE	NE	0	+ b
Sterling ^{21g}	25	-	2	13–15/kg	0	0	0	0	0

Table 4. Review of Previous Studies on UDCA in PSC

Gastroenterology Volume 129, Issue 5, November 2005, Pages 1464-1472





	Chazouillères et al ⁴⁴	Prospective	15	750-1250 mg	6	Improved liver function and symptoms		
	O'Brien et al. ⁴⁵	Open-label	12	10 mg/kg	30	Improved liver function and symptoms		
	Beuers et al. ⁴³	Double-blind, placebo-controlled	6	13-15 mg/kg	12	Improved liver function and histology. No effect on symptoms		
	Lo et al. ¹⁷⁵	Double-blind placebo controlled	23	10 mg/kg	24	Improved liver function. No effect on symptoms or histology		
	Stiehl et al. ¹⁷⁶	Double-blind, placebo-controlled	20	750 mg	12-48	Improved liver function and histology. No effect on symptoms		
	De Maria et al. ¹⁷⁷	Double-blind placebo controlled	59	600 mg	24	No improvement in liver function		
	Lindor 47	Double-blind, placebo-controlled	105	13-15 mg/kg	34	Improved liver function. No effect on histology and symptoms		
	Van Hoogstraten et al. ¹⁷⁸	Double-blind	48	10 mg/kg	24	Improved liver function. No effect on symptoms		
	Mitchell et al. ⁴⁹	Double-blind, placebo-controlled	26	20-25 mg/kg	24	Improved liver function, histology and cholangiography. No effect on symptoms. No survival benefit		
	Harnois et al. ¹⁷⁹	Open label	30	25-30 mg/kg	12	Improved liver function and survival compared with Mayo risk score		
	Okolicsanyi et al. ¹⁸⁰	Open-label, placebo-controlled	86	8-13 mg/kg	120	Improved liver function and symptoms. No effect on histology		
	Olsson et al. ⁵⁰	Multi-centre randomised Double-blind, placebo-controlled	219	17-23 mg/kg	60	Improved liver function. Nonsignificant trend towards increased survival. No effect on symptoms		
	Cullen et al. ⁵¹	Pilot dose range study	30	10 mg/kg 20 mg/kg 30 mg/kg	24	Improved projected survival with low and standard dose. Significantly improved projected survival with high dose		
CENT TORONTO WESTERN HO		Multi-centre Double-blind, placebo-controlled	150	28-30 mg/kg	60	Improved liver function. No improvement in symptoms or histology. Discontinued early (6 years): significantly risk of death, need for liver transplant or development of varicies	New York	

Meta-analysis pre-Lindor 2009

Table 1 Baseline characteristics of trials included in meta-analysis

Study, year	Publication type	Control	No. patients (UDCA/control)	Mean age (years)	Duration (months)	UDCA dose	ITT basis
Beuers et al., 1992 ⁶	Full text	Placebo	6/8	30/45.4	12	13–15 mg/kg/d	No
Lo et al., 1992 ¹⁸	Abstract	Placebo	8/10	NR	24	10 mg/kg/d	No
Stiehl et al., 19947	Full text	Placebo	10/10	36/41	3	750 mg/d	Yes
De Maria <i>et al.</i> , 1996 ¹⁹	Full text	No treatment	20/20	32.0/31.2	24	600 mg/d	No
Bansi <i>et al.</i> , 1996 ²⁰	Abstract	Placebo	12/11	NR	12	20 mg/kg/d	No
Lindor, 1997 ⁹	Full text	Placebo	53/52	41.7/43.8	26*	13-15 mg/kg/d	Yes
Mitchell et al., 20018	Full text	Placebo	13/13	52/52	24	20 mg/kg/d	Yes
Olsson <i>et al.</i> , 2005 ²¹	Full text	Placebo	110/109	43.6/43.1	60	17-23 mg/kg/d	Yes

*Mean.

ITT, intention-to-treat; NR, not reported; UDCA, ursodeoxycholic acid.



Hepatology Research 2009; **39**: 865–873

